ALPINE IMMUNE SCIENCES, INC.
Therapeutic antibodies and immunomodulatory proteins for immune-mediated diseases
- Sector
- Biotech
- Headquarters
- SEATTLE, WA
- Latest Form D
- $91M, Sep 2021
- Total capital
- $206M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $206M
- 4 Form D · last Sep 2021
- 61 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 24
- 16 pending · first 2022
- Rank in peer group#58 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$91M
- Private capital raisedForm D · SEC · 3rd filing$60M
- Private capital raisedForm D · SEC · 2nd filing$25.3M
- Private capital raisedForm D · SEC · 1st filing$30M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#58 · top 4%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Christopher James PeetzDirectorNamed in SEC Form D filings
- Cui Paul XiangminDirectorNamed in SEC Form D filings
- David H. MillerExecutive OfficerNamed in SEC Form D filings
- Dr. Mitchell H GoldExecutive Officer, DirectorNamed in SEC Form D filings
- James Paul RickeyExecutive OfficerNamed in SEC Form D filings
- James Paul TopperDirectorNamed in SEC Form D filings
Show all 19 people
- Jay Paul VenkatesanDirectorNamed in SEC Form D filings
- J. Paul H. RickeyExecutive OfficerNamed in SEC Form D filings
- Mark James LittonExecutive OfficerNamed in SEC Form D filings
- Michael H KornackerExecutive Officer, DirectorNamed in SEC Form D filings
- Mitchell Paul GoldExecutive Officer, DirectorNamed in SEC Form D filings
- Natasha Paul HerndayDirectorNamed in SEC Form D filings
- Paul James SekhriDirectorNamed in SEC Form D filings
- Peter James ThompsonDirectorNamed in SEC Form D filings
- Robert James ConwayDirectorNamed in SEC Form D filings
- Ryan H SwansonExecutive Officer, DirectorNamed in SEC Form D filings
- Stanford H. PangExecutive OfficerNamed in SEC Form D filings
- Stanford James PengExecutive OfficerNamed in SEC Form D filings
- Zelanna Paul GoldbergExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 24 granted of 40- GrantedVariant Icos Ligand Immunomodulatory Proteins And Related Compositions And MethodsUSPTOUS 12,692,299
- PendingCD86 Variant Immunomodulatory Proteins and Uses ThereofUSPTOApplication 19402705
- GrantedCD80 Variant Immunomodulatory Chimeric Proteins And Nucleic Acids Encoding For ThemUSPTOUS 12,668,634
Show all 40 patent records
- Variant Icos Ligand Immunomodulatory Proteins And Related Compositions And MethodsJul 28, 2026 · US 12,692,299Granted
- CD86 Variant Immunomodulatory Proteins and Uses ThereofJul 9, 2026 · Application 19402705Pending
- CD80 Variant Immunomodulatory Chimeric Proteins And Nucleic Acids Encoding For ThemJun 30, 2026 · US 12,668,634Granted
- CD155 Variant Immunomodulatory Proteins And Uses ThereofMay 12, 2026 · US 12,624,087Granted
- CTLA-4 Variant Immunomodulatory Proteins And Uses ThereofApr 28, 2026 · US 12,612,446Granted
- April And Baff Inhibitory Immunomodulatory Proteins And Methods Of Use ThereofApr 28, 2026 · US 12,612,447Granted
- PD-L1 Variant Immunomodulatory Proteins And Uses ThereofMar 5, 2026 · Application 19275190Pending
- CD86 Variant Immunomodulatory Proteins And Uses ThereofFeb 17, 2026 · US 12,552,853Granted
- Immunomodulatory Proteins With Tunable AffinitiesDec 2, 2025 · US 12,486,312Granted
- CTLA-4 Variant Immunomodulatory Proteins And Uses ThereofOct 16, 2025 · Application 19250472Pending
- Immunomodulatory Proteins Of Variant CD80 Polypeptides, Cell Therapies And Related Methods And UsesJul 31, 2025 · Application 18844376Pending
- CTLA-4 Variant Immunomodulatory Proteins And Uses ThereofJul 15, 2025 · US 12,358,969Granted
- Multi-domain Immunomodulatory Proteins And Methods Of Use ThereofMay 22, 2025 · Application 19026270Pending
- April And Baff Inhibitory Immunomodulatory Proteins And Methods Of Use ThereofMay 20, 2025 · US 12,304,943Granted
- Multi-domain Immunomodulatory Proteins And Methods Of Use ThereofMay 13, 2025 · US 12,297,253Granted
- April And Baff Inhibitory Immunomodulatory Proteins And Methods Of Use ThereofJan 21, 2025 · US 12,202,882Granted
- April And Baff Inhibitory Immunomodulatory Proteins And Methods Of Use ThereofJan 16, 2025 · Application 18895187Pending
- April And Baff Inhibitory Immunomodulatory Proteins And Methods Of Use ThereofJan 16, 2025 · Application 18895259Pending
- Icos Ligand Variant Immunomodulatory Proteins And Uses ThereofDec 12, 2024 · Application 18821680Pending
- PD-1 Variant Immunomodulatory Proteins And Uses ThereofOct 31, 2024 · Application 18767844Pending
- Icos Ligand Variant Immunomodulatory Proteins And Uses ThereofOct 8, 2024 · US 12,110,339Granted
- Methods Of Dosing And Treatment With A Taci-fc Fusion Immunomodulatory ProteinAug 22, 2024 · Application 18289746Pending
- PD-1 Variant Immunomodulatory Proteins And Uses ThereofAug 20, 2024 · US 12,065,476Granted
- CD80 Variant Immunomodulatory Proteins And Uses ThereofJan 4, 2024 · Application 18182308Pending
- CD112 Variant Immunomodulatory Proteins And Uses ThereofDec 5, 2023 · US 11,834,490Granted
- CTLA-4 Variant Immunomodulatory Proteins And Uses ThereofSep 12, 2023 · US 11,753,458Granted
- PD-L2 Variant Immunomodulatory Proteins And Uses ThereofAug 22, 2023 · US 11,732,022Granted
- April And Baff Inhibitory Immunomodulatory Proteins With And Without A T Cell Inhibitory Protein And Methods Of Use ThereofAug 3, 2023 · Application 17923208Pending
- Variant Icos Ligand Immunomodulatory Proteins And Related Compositions And MethodsJul 27, 2023 · Application 18172258Pending
- PD-L1 Variant Immunomodulatory Proteins And Uses ThereofJul 13, 2023 · Application 16493752Pending
- CD80 Variant Immunomodulatory Proteins And Uses ThereofMay 2, 2023 · US 11,639,375Granted
- Variant Icos Ligand Immunomodulatory Proteins And Related Compositions And MethodsMar 28, 2023 · US 11,613,566Granted
- CD80 Variant Immunomodulatory Proteins And Uses ThereofNov 15, 2022 · US 11,498,967Granted
- CD80 Variant Immunomodulatory Proteins And Uses ThereofOct 25, 2022 · US 11,479,609Granted
- CD155 Variant Immunomodulatory Proteins And Uses ThereofOct 18, 2022 · US 11,471,488Granted
- Methods And Uses Of Variant Icos Ligand (icosl) Fusion ProteinsJul 14, 2022 · Application 17603827Pending
- CD80 Variant Immunomodulatory Proteins And Uses ThereofJun 14, 2022 · US 11,359,022Granted
- Methods And Uses Of Variant CD80 Fusion Proteins And Related ConstructsJun 9, 2022 · Application 17275646Pending
- Immunomodulatory Proteins With Tunable AffinitiesMay 3, 2022 · US 11,319,359Granted
- April And Baff Inhibitory Immunomodulatory Proteins And Methods Of Use ThereofMar 15, 2022 · US 11,274,140Granted
Related companies, and why
- New Frontier Bio, Inc.Similar federal contract value in Biotech · null in contracts
- Lattice Biologics Ltd.Similar federal contract value in Biotech · null in contracts
- EnGeneIC LtdSimilar federal contract value in Biotech · null in contracts
- Okogen, Inc.Similar federal contract value in Biotech · null in contracts
- Protagenic Therapeutics, Inc.\newSimilar federal contract value in Biotech · null in contracts
- GREENLAB, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .